Also found in: Dictionary.
Related to Pronestyl: Procainamide
Pregnancy Category: C
Treatment of a wide variety of ventricular and atrial arrhythmias, including:
- Atrial premature contractions,
- Premature ventricular contractions,
- Ventricular tachycardia,
- Paroxysmal atrial tachycardia.
Decreases myocardial excitability.
Slows conduction velocity.
May depress myocardial contractility.
Suppression of arrhythmias.
Absorption: Well absorbed (75–90%) following IM administration.
Distribution: Rapidly and widely distributed.
Metabolism and Excretion: Converted by the liver to N-acetylprocainamide (NAPA), an active antiarrhythmic compound. Remainder (40–70%) excreted unchanged by the kidneys.
Half-life: 2.5–4.7 hr (NAPA—7 hr); ↑ in renal impairment.
Time/action profile (antiarrhythmic effects)
|IV||immediate||25–60 min||3–4 hr|
|IM||10–30 min||15–60 min||3–4 hr|
Contraindicated in: Hypersensitivity;AV block;Myasthenia gravis.
Use Cautiously in: MI or digoxin toxicity;HF, renal dysfunction, or hepatic dysfunction (dose ↓ recommended); Geriatric: Dose ↓ recommended); Obstetric / Lactation / Pediatric: Safety not established.
Adverse Reactions/Side Effects
Central nervous system
- seizures (life-threatening)
- asystole (life-threatening)
- heart block (life-threatening)
- ventricular arrhythmias (life-threatening)
- diarrhea (most frequent)
- bitter taste
- agranulocytosis (life-threatening)
- drug-induced systemic lupus syndrome
Drug-Drug interactionMay have additive or antagonistic effects with other antiarrhythmics.Additive neurologic toxicity (confusion, seizures) with lidocaine.Antihypertensives and nitrates may potentiate hypotensive effect.Potentiates neuromuscular blocking agents.May partially antagonize the therapeutic effects of anticholinesterase agents in myasthenia gravis.↑ risk of arrhythmias with pimozide.Additive anticholinergic effects with other drugs possessing anticholinergic properties, including antihistamines, antidepressants, atropine, haloperidol, and phenothiazines.Effects of procainamide may be ↑ by cimetidine, quinidine, or trimethoprim.
Intramuscular (Adults) 50 mg/kg/day in divided doses q 3–6 hr.
Intravenous (Adults) 100 mg q 5 min until arrhythmia is abolished or 1000 mg have been given; wait at least 10 min until further dosing or loading infusion of 500–600 mg over 30–60 min followed by maintenance infusion of 1–4 mg/min.
Availability (generic available)
Injection: 100 mg/mL, 500 mg/mL
- Monitor ECG, pulse, and BP continuously throughout IV administration. Parameters should be monitored periodically during oral administration. IV administration is usually discontinued if any of the following occur: arrhythmia is resolved, QRS complex widens by 50%, PR interval is prolonged, BP drops >15 mm Hg, or toxic side effects develop. Patient should remain supine throughout IV administration to minimize hypotension.
- Lab Test Considerations: Monitor CBC every 2 wk during the first 3 mo of therapy. May cause ↓ leukocyte, neutrophil, and platelet counts. Therapy may be discontinued if leukopenia occurs. Blood counts usually return to normal within 1 mo of discontinuation of therapy.
- Monitor ANA periodically during prolonged therapy or if symptoms of lupus-like reaction occur. Therapy is discontinued if a steady increase in ANA titer occurs.
Serum procainamide and N-acetylprocainamide levels may be monitored periodically during dosage adjustment. Therapeutic blood level of procainamide is 4–8 mcg/mL.
- May cause ↑ AST, ALT, alkaline phosphatase, LDH, bilirubin, and a positive Coombs’ test result.
- Toxicity may occur with procainamide blood levels of 8–16 mcg/mL or greater.
- Signs of toxicity include confusion, dizziness, drowsiness, decreased urination, nausea, vomiting, and tachyarrhythmias.
Potential Nursing DiagnosesDecreased cardiac output (Indications)
- Intramuscular: Used only when IV route is not feasible.
- pH: 4.0–6.0.
- (only to be used for life-threatening arrhythmias).Diluent: Dilute each 100 mg of procainamide with 10 mL of 0.9% NaCl.
- Rate: Not to exceed 25 mg/min. Rapid administration may cause ventricular fibrillation or asystole.
- Intermittent Infusion: (preferred route of administration)Diluent: Add 2 g of procainamide to 250 mL of 0.9% NaCl. Concentration: 8 mg/mL.
- Rate: Administer initial infusion over 30–60 min. Administer maintenance infusion at rate of 1–4 mg/min to maintain control of arrhythmia.
- Y-Site Compatibility: alemtuzumab, alfentanil, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, argatroban, ascorbic acid, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride, calcium gluconate, caspofungin, cefazolin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, chlorpromazine, cisatracurium, cisplatin, clindamycin, cyanocobalamin, cyclophosphamide, cyclosporine, cytarabine, dactinomycin, daptomycin, dexamethasone, dexmedetomidine, digoxin, diphenhydramine, dobutamine, docetaxel, dopamine, doxacurium, doxorubicin, doxycycline, enalaprilat, ephedrine, epinephrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentanyl, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hetastarch, hydrocortisone, hydromorphone, idarubicin, ifosfamide, indomethacin, insulin, irinotecan, isoproterenol, ketorolac, labetalol, lidocaine, linezolid, lorazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methotrexate, methoxamine, methyldopate, methylprednisolone, metoclopramide, metoprolol, midazolam, mitoxantrone, morphine, multivitamins, mycophenolate, nafcillin, nalbuphine, naloxone, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, pemetrexed, penicillin G, pentamidine, pentazocine, pentobarbital, phenobarbital, phentolamine, phenylephrine, phytonadione, piperacillin/tazobactam, potassium acetate, potassium chloride, prochlorperazine, promethazine, propranolol, protamine, pyridoxime, quinupristin/dalfopristin, ranitidine, remifentanil, rocuronium, sodium bicarbonate, streptokinase, succinylcholine, sufentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimetaphan, vancomycin, vasopressin, vecuronium, verapamil, vincristine, vinorelbine, vitamin B complex with C, voriconazole, zoledronic acid
- Y-Site Incompatibility: acyclovir, azathioprine, carboplatin, carmustine, chloramphenicol, dantrolene, diazepam, diazoxide, ganciclovir, hydralazine, metronidazole, milrinone, phenytointrimethoprim/sulfamethoxazole.
- May cause dizziness. Caution patient to request assistance with ambulation until response to medication is known.
- Advise patient to notify health care professional immediately if signs of drug-induced lupus syndrome (fever, chills, joint pain or swelling, pain with breathing, skin rash), leukopenia (sore throat, mouth, or gums), or thrombocytopenia (unusual bleeding or bruising) occur. Medication may be discontinued if these occur.
- Advise patient to carry identification at all times describing disease process and medication regimen.
- Emphasize the importance of routine follow-up exams to monitor progress.
- Resolution of cardiac arrhythmias without detrimental side effects.